Patients harbouring cancers with high FOXC2 mRNA expression level showed shorter time to biochemical recurrence (p = 0.006) (Figure 3), and a similar result was observed among Gleason score 7 carcinomas (n = 44; p = 0.003). Here, FOXC2 is linked to carcinoma.